Enhancing Capital’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$9.96M Hold
8,300
6.84% 1
2026
Q1
$7.63M Hold
8,300
5.66% 2
2025
Q4
$8.92M Hold
8,300
6.38% 2
2025
Q3
$6.33M Hold
8,300
4.63% 4
2025
Q2
$6.47M Hold
8,300
4.93% 3
2025
Q1
$6.86M Hold
8,300
5.48% 2
2024
Q4
$6.41M Buy
+8,300
New +$6.87M 5.11% 2
2022
Q3
$2.71M Hold
8,300
3.35% 5
2022
Q2
$2.69M Hold
8,300
3.21% 8
2022
Q1
$2.38M Hold
8,300
2.54% 10
2021
Q4
$2.29M Buy
+8,300
New +$2.1M 2.49% 12

Other funds holding LLY

Enhancing Capital's LLY Position: Q2 2026 in Review

Enhancing Capital held its Eli Lilly (LLY) position steady in Q2 2026 at 8,300 shares worth $9.96M. The position accounts for 6.84% of the portfolio, ranked #1.

Enhancing Capital first reported a position in LLY in Q4 2021 and has held it in 11 quarters since. 4,630 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Enhancing Capital held 8,300 shares of Eli Lilly worth $9.96M as of Q2 2026.
  • Enhancing Capital left its Eli Lilly share count unchanged in Q2 2026.
  • Eli Lilly made up 6.84% of Enhancing Capital's portfolio in Q2 2026, its #1 holding.
  • Enhancing Capital first reported a position in Eli Lilly in Q4 2021 and has held it in 11 quarters since.
  • 4,630 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Enhancing Capital's 13F filing for Q2 2026, filed 11 Aug 2026.